Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents

被引：0
|
作者：
Finn, R. S.
Lau, A.
Kalous, O.
Conklin, D.
Dering, J.
Knights, C.
O'Shaughnessy, A.
Cranston, A.
Riches, L.
Carmichael, J.
O'Connor, M. J.
Slamon, D. J.
机构：
[1] KuDOS Pharmaceut, Cambridge, England
[2] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90024 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117S / 117S
页数：1
相关论文
共 50 条
  • [31] Accelerating Combination Drug Therapies for Triple Negative Breast Cancer through Comparative Pre-Clinical Testing of Human Xenografts and a Mouse Breast Cancer Model
    Bennett, C. N.
    Tomlinson, C. C.
    Hollingshead, M. G.
    Green, J. E.
    CANCER RESEARCH, 2009, 69 (24) : 646S - 646S
  • [32] Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines
    Cascone, T.
    Morgillo, F.
    Laus, G.
    Pepe, S.
    Ciardiello, F.
    EJC SUPPLEMENTS, 2006, 4 (12): : 122 - 122
  • [33] In vitro efficacy of dasatinib alone or in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer cell lines
    Sun, Yuliang
    Carlson, Jennifer
    Lin, Xiaoqian
    De, Pradip
    Williams, Casey
    Hausman, Sally
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2016, 76
  • [34] Antitumor DNA-Damaging C-1748 is a New Inhibitor of Autophagy that Triggers Apoptosis in Human Pancreatic Cancer Cell Lines
    Borowa-Mazgaj, Barbara
    Skwarska, Anna
    Augustin, Ewa
    Radominska-Pandya, Anna
    Mazerska, Zofia
    FASEB JOURNAL, 2016, 30
  • [35] Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells
    Gu, Wei Wei
    Lin, Jie
    Hong, Xing Yu
    ONCOTARGET, 2017, 8 (53) : 90842 - 90851
  • [36] Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines
    Witters, LM
    Crispino, J
    Fraterrigo, T
    Green, J
    Lipton, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : S92 - S97
  • [37] The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response
    Gaudio, Eugenio
    Kwee, Ivo
    Tarantelli, Chiara
    Bernasconi, Elena
    Rinaldi, Andrea
    Cascione, Luciano
    Ponzoni, Maurilio
    Stathis, Anastasios
    Zucca, Emanuele
    Goodstal, Samantha
    Bertoni, Francesco
    CANCER RESEARCH, 2014, 74 (19)
  • [38] Synergistic activity of PI3K inhibitor in combination with AZD6738, ATR inhibitor in breast cancer preclinical model via DNA damage response pathway
    Moon, Yong Wha
    Gosh, Mithun
    Park, Nahee
    Pandey, Kamal
    Katwal, Nar Bahadur
    Hong, Sa Deok
    CANCER RESEARCH, 2023, 83 (05)
  • [39] Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers
    Tosoni, Daniela
    Pambianco, Sarah
    Soppo, Blanche Ekalle
    Zecchini, Silvia
    Bertalot, Giovanni
    Pruneri, Giancarlo
    Viale, Giuseppe
    Di Fiore, Pier Paolo
    Pece, Salvatore
    EMBO MOLECULAR MEDICINE, 2017, 9 (05) : 655 - 671
  • [40] Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer
    Gordhandas, Sushmita B.
    Manning-Geist, Beryl
    Henson, Christina
    Iyer, Gopa
    Gardner, Ginger J.
    Sonoda, Yukio
    Moore, Kathleen N.
    Aghajanian, Carol
    Chui, M. Herman
    Grisham, Rachel N.
    SCIENTIFIC REPORTS, 2022, 12 (01)
12345